Faith E. Nathan

9.3k total citations · 2 hit papers
45 papers, 2.1k citations indexed

About

Faith E. Nathan is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Faith E. Nathan has authored 45 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Oncology, 29 papers in Pulmonary and Respiratory Medicine and 6 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Faith E. Nathan's work include Cancer Immunotherapy and Biomarkers (17 papers), Lung Cancer Treatments and Mutations (15 papers) and Prostate Cancer Treatment and Research (14 papers). Faith E. Nathan is often cited by papers focused on Cancer Immunotherapy and Biomarkers (17 papers), Lung Cancer Treatments and Mutations (15 papers) and Prostate Cancer Treatment and Research (14 papers). Faith E. Nathan collaborates with scholars based in United States, Germany and Australia. Faith E. Nathan's co-authors include Julie R. Brahmer, Hossein Borghaei, Matthew D. Hellmann, Naiyer A. Rizvi, Rosalyn A. Juergens, Scott Gettinger, Scott Antonia, Christopher Harbison, Jonathan W. Goldman and David E. Gerber and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Faith E. Nathan

44 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

2016 394 citations Scott Gettinger, Naiyer A. Rizvi et al. Journal of Clinical Oncology profile →
Nivolumab in Combination With Platinum‐Based Doublet Chemotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

2016 350 citations Naiyer A. Rizvi, Matthew D. Hellmann et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Faith E. Nathan

Since Specialization

Citations

This map shows the geographic impact of Faith E. Nathan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Faith E. Nathan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Faith E. Nathan more than expected).

Fields of papers citing papers by Faith E. Nathan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Faith E. Nathan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Faith E. Nathan. The network helps show where Faith E. Nathan may publish in the future.

Co-authorship network of co-authors of Faith E. Nathan

This figure shows the co-authorship network connecting the top 25 collaborators of Faith E. Nathan. A scholar is included among the top collaborators of Faith E. Nathan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Faith E. Nathan. Faith E. Nathan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial 2023 ·ESMO Open ·Hossein Borghaei, Kenneth J. O’Byrne, Luis Paz‐Ares, T-E. Ciuleanu, (unknown), Adam Płużański, Adnan Nagrial, Libor Havel, Rubén Dario Kowalyszyn, Clarisse Audigier-Valette, Julie R. Brahmer, Martin Reck, (unknown), Li Zhang, (unknown), Sridhar K. Rabindran, Faith E. Nathan, David Balli, Yi‐Long Wu	23
2	First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients 2022 ·ESMO Open ·Kenneth J. O’Byrne, (unknown), (unknown), (unknown), Makoto Nishio, Hiroshi Sakai, Yuichiro Ohe, Tatsuro Fukuhara, (unknown), Haruko Daga, Chong‐Jen Yu, Katsuyuki Hotta, Hiroshi Tanaka, Masayuki Takeda, Toshihide Yokoyama, Faith E. Nathan, J.-S. Lee	14
3	OA03.03 Nivolumab (NIVO) + ipilimumab (IPI) Versus Platinum-Doublet Chemotherapy (Chemo) as First-Line (1L) Treatment for Advanced Non-Small Cell Lung Cancer (aNSCLC): 3-year Update from CheckMate 227 Part 1 2021 ·Journal of Thoracic Oncology ·(unknown), Tudor–Eliade Ciuleanu, Adam Płużański, J.-S. Lee, Michael Schenker, (unknown), (unknown), Bogdan Żurawski, Clarisse Audigier-Valette, Mariano Provencio, Helena Linardou, (unknown), Hossein Borghaei, Matthew D. Hellmann, Kenneth J. O’Byrne, Luis Paz‐Ares, Martin Reck, Faith E. Nathan, Julie R. Brahmer	2
4	1274P First-line (1L) nivolumab (NIVO) plus ipilimumab (IPI) in Asian patients (pts) with advanced non-small cell lung cancer (aNSCLC) in CheckMate 227 2020 ·Annals of Oncology ·Kenneth J. O’Byrne, (unknown), S-W. Kim, (unknown), Makoto Nishio, Hiroshi Sakai, Yuichiro Ohe, Tatsuro Fukuhara, Jae‐Heon Kang, (unknown), Chong‐Jen Yu, Katsuyuki Hotta, Hiroshi Tanaka, Masayuki Takeda, Toshihide Yokoyama, Faith E. Nathan, Jin Sun Lee	3
5	CheckMate 227: A randomized, open-label phase 3 trial of nivolumab, nivolumab plus ipilimumab, or nivolumab plus chemotherapy versus chemotherapy in chemotherapy-naïve patients with advanced non-small cell lung cancer (NSCLC) 2017 ·Annals of Oncology ·Luis Paz‐Ares, Julie R. Brahmer, Matthew D. Hellmann, Martin Reck, Kenneth J. O’Byrne, Hossein Borghaei, William J. Geese, Haolan Lu, Faith E. Nathan, Suresh S. Ramalingam	9
6	First-line monotherapy with nivolumab (NIVO; anti-programmed death-1 [PD-1]) in advanced non-small cell lung cancer (NSCLC): Safety, efficacy and correlation of outcomes with PD-1 ligand (PD-L1) expression. 2015 ·Journal of Clinical Oncology ·Scott Gettinger, Matthew D. Hellmann, Frances A. Shepherd, Scott Antonia, Julie R. Brahmer, Laura Q.M. Chow, Jonathan W. Goldman, Rosalyn A. Juergens, Hossein Borghaei, Neal Ready, David E. Gerber, Faith E. Nathan, Yun Shen, Christopher Harbison, Naiyer A. Rizvi	34
7	Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer 2013 ·Prostate Cancer and Prostatic Diseases ·K. Miller, Judd W. Moul, Martin Gleave, Karim Fizazi, James B. Nelson, Thomas Morris, Faith E. Nathan, Stuart McIntosh, Kristine Pemberton, Celestia S. Higano	64
8	A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14) 2012 ·Gynecologic Oncology ·Francesco Cognetti, Anna Bagnato, Nicoletta Colombo, Antonella Savarese, Giovanni Scambia, Jalid Sehouli, Pauline Wimberger, Roberto Sorio, Philipp Harter, E. Mari, Stuart McIntosh, Faith E. Nathan, Kristine Pemberton, Klaus Baumann	15
9	Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration‐resistant prostate cancer 2011 ·The Prostate ·Donald L. Trump, Heather Payne, Kurt Miller, Johann S. de Bono, Joe Stephenson, Howard A. Burris, Faith E. Nathan, Maria Taboada, Thomas Morris, Andreas Hübner	16
10	Pain in castration-resistant prostate cancer with bone metastases: a qualitative study 2011 ·Health and Quality of Life Outcomes ·Adam Gater, Linda Abetz‐Webb, (unknown), Bhash Parasuraman, Stuart McIntosh, Faith E. Nathan, Elisabeth Piault	30
11	Economic burden and healthcare utilization associated with castration-resistant prostate cancer in a commercial and Medicare Advantage US patient population 2010 ·Journal of Medical Economics ·(unknown), Erin Buysman, David Parry, Laura Becker, Faith E. Nathan	41
12	A phase II, randomized, multicenter study to assess the efficacy, safety, and tolerability of zibotentan (ZD4054) in combination with pemetrexed in patients with advanced non-small cell lung cancer 2010 ·Cancer Chemotherapy and Pharmacology ·C. Chouaïd, Faith E. Nathan, Kristine Pemberton, Thomas Morris	13
13	Phase I study of the effects of hepatic impairment on the pharmacokinetic (PK) and safety of satraplatin in patients with refractory non-hematologic cancer 2006 ·Journal of Clinical Oncology ·(unknown), Gavin Preston, Christopher B. Jones, John Sarantopoulos, T.E. Dufresne, Michael E. Petrone, Faith E. Nathan, Douglas S. Greene, Tiffany Anthony, (unknown)	2
14	Satraplatin: A new treatment option for patients with hormone refractory prostate cancer 2005 ·Journal of Clinical Oncology ·Faith E. Nathan, C. Sternberg, Oliver Sartor, Daniel P. Petrylak, Fred Witjes, Katja Wosikowski, Michael E. Petrone, Marcel Rozencweig	4
15	Paclitaxel and tamoxifen 2000 ·Cancer ·Faith E. Nathan, David Berd, Takami Sato, Michael J. Mastrangelo	39
16	Systemic therapy in melanoma 1998 ·Seminars in Surgical Oncology ·Faith E. Nathan, Michael J. Mastrangelo	24
17	Cutaneous angiosarcoma with eyelid involvement 1998 ·American Journal of Ophthalmology ·Kaan Gündüz, Jerry A. Shields, Carol L. Shields, Ralph C. Eagle, Faith E. Nathan	33
18	Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. 1997 ·Journal of Clinical Oncology ·G. R. Hudes, Faith E. Nathan, (unknown), Naomi B. Haas, (unknown), Bruce J. Giantonio, Richard E. Greenberg, Leonard G. Gomella, Samuel Litwin, Eric A. Ross, Susan K. Roethke, C McAleer	206
19	Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer. 1995 ·PubMed ·G. R. Hudes, Faith E. Nathan, (unknown), Richard H. Greenberg, Leonard G. Gomella, C. Stern, C McAleer	59
20	Plasma thrombospondin levels in patients with gynecologic malignancies 1994 ·Cancer ·Faith E. Nathan, Enrique Hernández, Charles J. Dunton, Joseph Treat, Hanna I. Switalska, Rosaline R. Joseph, George P. Tuszynski	51

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact